{"page_content": "Who We Are   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2\nAlloCAR T\u2122 Products:  \nImproving Access to Cell Therapy   . . . . . . . . . . . . . . . . . . 3\nValuing Our People   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5\nOur Allogene Community   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6\nOur One Allogene  Culture   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7\nCancer Doesn\u2019t Discriminate and Neither Do We   . . . . . . . . . . . . . 9\nStaying Connected and Informed   . . . . . . . . . . . . . . . . . . . . . . . . . . 11\nSafety in the Workplace   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12\nRecruiting, Developing and Retaining Talent   . . . . . . . 14\nCompensation & Benefits   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15\nCareer Development   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16\nSpot Recognition through Allogene\u2019s Gratitude Lab   . . . . . . . . . 16Prioritizing Environmental Sustainability   . . . . . . . . . . . 17\nThe Facility of the Future: Cell Forge 1   . . . . . . . . . . . . . . . . . . . . . . 19\nCurrent Initiatives to Reduce Environmental Impact   . . . . . . . . . 20\nOur Focus for the Future   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20\nPursuing the Highest Ethical Standards   . . . . . . . . . . . . 21\nAllogene\u2019s Board and Corporate Governance   . . . . . . . . . . . . . . . 21\nBusiness Ethics and Human Rights   . . . . . . . . . . . . . . . . . . . . . . . . . 22\nClinical Trials   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23\nProduct Quality and Patient Safety   . . . . . . . . . . . . . . . . . . . . . . . . 24\nSupply Chain and Partners   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24\nManaging Cybersecurity Risk   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25CONTENTS \n", "metadata": {"source": "NASDAQ_ALLO_2022.pdf", "page": 1, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}